US equities |
MU $944.36 ▼-4.52% META $759.35 ▲+2.21% NVDA $226.95 ▲+0.28% SNDK $1,460.70 ▼-1.79% AAPL $344.60 ▲+1.06% SPCX $157.28 ▼-3.76% MSFT $546.37 ▲+0.96% AMD $598.96 ▲+0.79%
FinancialContent

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

42.98 +0.17 (+0.41%)
Delayed Quote Updated: 12:37 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
1 Healthcare Stock Worth Your Attention and 2 We Turn Down
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on... 
Via StockStory
News headline image
1 Unprofitable Stock with Impressive Fundamentals and 2 We Avoid
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
2 Growth Stocks to Add to Your Roster and 1 We Question
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
Topics Credit Cards
News headline image
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
3 Reasons SUPN is Risky and 1 Stock to Buy Instead
Over the last six months, Supernus Pharmaceuticals’s shares have sunk to $41.99, producing a disappointing 14.7% loss - a stark contrast to the S&P 500’s 16.... 
Via StockStory
Topics Stocks Supply Chain
News headline image
Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Supernus Pharmaceuticals (NAS... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Cash-Heavy Stocks Walking a Fine Line
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
Via StockStory
News headline image
1 of Wall Street’s Favorite Stocks with Promising Prospects and 2 Facing Headwinds
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
Supernus Pharmaceuticals to Participate in September Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Out-of-Favor Stocks We’re Skeptical Of
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether... 
Via StockStory
News headline image
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
3 Small-Cap Stocks with Open Questions
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
1 Healthcare Stock with Exciting Potential and 2 We Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
Topics Retirement
News headline image
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗
Supernus Pharmaceuticals (NASDAQ:SUPN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs.... 
Via Benzinga
Topics Earnings
News headline image
3 Russell 2000 Stocks We Approach with Caution
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ... 
Via StockStory
News headline image
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Why Supernus Pharmaceuticals Stock Topped the Market Today ↗
It's effecting a "merger of equals" with a peer. 
Via The Motley Fool
News headline image
Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Supernus Pharmaceuticals Q2 Earnings Call Highlights ↗
Supernus Pharmaceuticals (NASDAQ:SUPN) and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals that would create a central nervous system-focused biopharmaceutical... 
Via MarketBeat
Topics Earnings
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 3... 
Via StockStory
News headline image
Supernus Announces Second Quarter 2026 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
From Supernus Pharmaceuticals, Inc.; Indivior Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting results this Tuesday after market hours. Here’s what to look for. S... 
Via StockStory
Topics Artificial Intelligence
News headline image
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
1 Growth Stock to Stash and 2 We Turn Down
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
Topics Artificial Intelligence
News headline image
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >